MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12029-022-00867-3

Медицинская библиотека · Journal of gastrointestinal cancer · 2022

Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.

Ramaswamy Anant, Bhargava Prabhat, Srinivas Sujay, Kannan Sadhana, Bhandare Manish, Chaudhari Vikram, Mantri Anoop, Kapoor Akhil, Das Sudeep, Booma Naveen, Chaugule Deepali, Shrikhande Shailesh V, Ostwal Vikas

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVES

There is limited real-world data on the efficacy of 2-weekly cycles of docetaxel, oxaliplatin, leucovorin, and fluorouracil (FLOT) compared to epirubicin, oxaliplatin, and capecitabine (EOX) as perioperative therapy in esophagogastric adenocarcinomas (EGAC).

METHODS

The data of 611 patients with EGAC treated with perioperative chemotherapy and planned for curative resection between January 2013 and December 2019 were retrieved. Patients receiving EOX and a dose-modified version of FLOT (mFLOT) were evaluated. A 1:1 matching, using age, tumour location, signet ring histology, and Eastern Cooperative Oncology Group performance status, without replacement was performed by using nearest neighbour matching method. The primary endpoint of the study was 3-year event-free survival (EFS).

RESULTS

A total of 593 patients (261 with EOX and 332 with mFLOT) were matched. One hundred and nighty-eight patients (76%) and 285 patients (86%) in the EOX and mFLOT cohorts underwent curative resection, respectively (p = 0.002). With a median follow-up of 35 and 53 months, respectively, the primary outcome of 3-year EFS was statistically superior in patients receiving mFLOT as compared to the EOX regimen (60% vs. 39%; p < 0.001). There was a greater incidence of grade 3 and grade 4 neutropenia (neoadjuvant: 18% vs. 2%; p < 0.001, adjuvant: 18% vs. 1%; p = 0.001) and febrile neutropenia (neoadjuvant: 8% vs. 1.1%; p < 0.001, adjuvant: 6% vs. 0; p = 0.001) with mFLOT.

INTERPRETATION AND

CONCLUSION

mFLOT is associated with improved resection rates and survival in comparison to EOX as perioperative therapy in gastric adenocarcinomas in this large real-world cohort, with manageable increase in clinically relevant toxicities such as grade 3 and grade 4 febrile neutropenia and neutropenia.

Для цитирования: Ramaswamy Anant, Bhargava Prabhat, Srinivas Sujay, Kannan Sadhana, Bhandare Manish, Chaudhari Vikram, Mantri Anoop, Kapoor Akhil, Das Sudeep, Booma Naveen, Chaugule Deepali, Shrikhande Shailesh V, Ostwal Vikas. Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.. Journal of gastrointestinal cancer. 2022. DOI: 10.1007/s12029-022-00867-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.